Skip to content
MedsAcross

Medicine

Metaxalone 400 mg tablet

Metaxalone · Oral
Available on requestPrescription onlyUS FDAGeneric name

Metaxalone 400 mg tablet is a generic prescription medicine for oral use, made by 6 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77°F).

Key facts

Active ingredient (INN)
Metaxalone
Brand
Sold under the generic name
Strength
400 mg
Dosage form
Tablet
Route
Oral
Packs
100 tablets, 1000 tablets, 30 tablets and 4 more
Manufacturers
CiplaIndiaScieGen PharmaceuticalsAmneal Pharmaceuticals of New YorkBlue Heron PharmaceuticalsHighmark PharmaMisemer Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
26 May 2016
Identifiers
RxCUI 197935, 351254DailyMed set ID de3448df-4ca1-44ec-bad1-486549cddf64, d0276e7b-a1c9-61f3-e053-2a95a90ae3aa, 1cef46bb-e590-4a58-82e0-7cf1fc3836a5 +3NDC 0115-1745, 0276-0508, 50228-474 +3Application ANDA040486, ANDA207466

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
100 tablet in 1 bottle69097-998-07CiplaIndia12 June 2023
100 tablet in 1 bottle0115-1745-01Amneal Pharmaceuticals of New York26 May 2016
100 tablet in 1 bottle85622-950-10Blue Heron Pharmaceuticals15 September 2026
100 tablet in 1 bottle87450-101-10Highmark Pharma26 April 2026
100 tablet in 1 bottle0276-0508-10Misemer Pharmaceuticals1 November 2021
1000 tablet in 1 bottle50228-474-10ScieGen Pharmaceuticals30 April 2020
30 tablet in 1 bottle50228-474-30ScieGen Pharmaceuticals30 April 2020

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 13 August 1962Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Metaxalone

Clinical summary

Metaxalone is a muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adults, among other approved uses. MedsAcross supplies Metaxalone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Metaxalone

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Metaxalone 400 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.